Worth Watching: Axovant Sciences Ltd Just Recorded A Sigfniciant Increase

Worth Watching: Axovant Sciences Ltd Just Recorded A Sigfniciant Increase

The stock of Axovant Sciences Ltd (NYSE:AXON) is a huge mover today! The stock increased 4.98% or $0.67 on November 23, hitting $14.12. About 381,251 shares traded hands or 46.65% up from the average. Axovant Sciences Ltd (NYSE:AXON) has risen 2.47% since April 22, 2016 and is uptrending. It has underperformed by 2.94% the S&P500.
The move comes after 9 months positive chart setup for the $1.40B company. It was reported on Nov, 24 by Barchart.com. We have $14.83 PT which if reached, will make NYSE:AXON worth $70.00M more.

Analysts await Axovant Sciences Ltd (NYSE:AXON) to report earnings on February, 14. They expect $-0.45 earnings per share, up 29.69% or $0.19 from last year’s $-0.64 per share. After $-0.43 actual earnings per share reported by Axovant Sciences Ltd for the previous quarter, Wall Street now forecasts 4.65% negative EPS growth.

Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage

Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained the shares of AXON in a report on Friday, September 25 with “Sell” rating. The firm has “Overweight” rating by Piper Jaffray given on Thursday, October 22. The stock has “Buy” rating given by H.C. Wainwright on Friday, January 8. The firm has “Outperform” rating given on Tuesday, June 7 by Leerink Swann.

According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”

More notable recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Prnewswire.com which released: “Axovant Sciences to Present at Upcoming Investor Conferences” on September 26, 2016, also Fool.com with their article: “Why Axovant Sciences Skyrocketed 56% in November” published on December 03, 2015, Nasdaq.com published: “Commit To Buy Axovant Sciences At $5, Earn 38% Using Options” on November 22, 2016. More interesting news about Axovant Sciences Ltd (NYSE:AXON) were released by: Fool.com and their article: “Why Axovant Sciences Shares Are Crashing” published on February 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Axovant Sciences Ltd.AXON” with publication date: June 05, 2015.

AXON Company Profile

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment